Medical compositions containing ghrelin

ABSTRACT

It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 μmol/mL.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is continuation application of U.S. patent applicationSer. No. 10/500,561, now abandoned, which is a National StageApplication of International Application No. PCT/JP03/06349, filed May21, 2003, which claims priority to Japanese Application 2002-146155,filed on May 21, 2002, the disclosure of each of which are herebyincorporated by reference in their entireties.

BACKGROUND OF THE INVENTION

(i) Field of the Invention

The present invention relates to a pharmaceutical composition containingghrelin or derivative thereof, which is an endogenous growth hormonesecretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R) ina stable state, as well as to a method for preventing degradation ofmodifying hydrophobic group of ghrelin or its derivative in an aqueoussolution dissolved ghrelin or its derivative therein.

(ii) Description of the Related Art

Ghrelin, an endogenous growth hormone secretagogue (GHS) to growthhormone secretagogue receptor (GHS-R) which is one of orphan receptors,is a physiologically active peptide first isolated and purified from ratin 1999 (Kojima, et al., Nature, 402: 656-660, 1999). Thereafter, someghrelins having same chemical structure of rat ghrelin have beenisolated from vertebrates other than rat, such as human, mouse, pig,chicken, eel, bovine, equine, ovine, frog, trout and canine. Thechemical structures of these ghrelins are listed in the following Table1.

TABLE 1 Human GSS(n-octanoyl)FLSPEHQRVQQRKESKKPPAKLQPR (SEQ ID NO: 1)GSS(n-octanoyl)FLSPEHQRVQRKESKKPPAKLQPR (SEQ ID NO: 2) RatGSS(n-octanoyl)FLSPEHQKAQQRKESKKPPAKLQPR (SEQ ID NO: 3)GSS(n-octanoyl)FLSPEHQKAQRKESKKPPAKLQPR (SEQ ID NO: 4) MouseGSS(n-octanoyl)FLSPEHQKAQQRKESKKPPAKLQPR (SEQ ID NO: 5) PorcineGSS(n-octanoyl)FLSPEHQKVQQRKESKKPAAKLKPR (SEQ ID NO: 6) BovineGSS(n-octanoyl)FLSPEHQKLQRKEAKKPSGRLKPR (SEQ ID NO: 7) OvineGSS(n-octanoyl)FLSPEHQKLQRKEPKKPSGRLKPR (SEQ ID NO: 8) CanineGSS(n-octanoyl)FLSPEHQKLQQRKESKKPPAKLQPR (SEQ ID NO: 9) EelGSS(n-octanoyl)FLSPSQRPQGKDKKPPRV-NH₂ (SEQ ID NO: 10) TroutGSS(n-octanoyl)FLSPSQKPQVRQGKGKPPRV-NH₂ (SEQ ID NO: 11)GSS(n-octanoyl)FLSPSQKPQGKGKPPRV-NH₂ (SEQ ID NO: 12) ChickenGSS(n-octanoyl)FLSPTYKNIQQQKGTRKPTAR (SEQ ID NO: 13)GSS(n-octanoyl)FLSPTYKNIQQQKDTRKPTAR (SEQ ID NO: 14)GSS(n-octanoyl)FLSPTYKNIQQQKDTRKPTARLH (SEQ ID NO: 15) BullfrogGLT(n-octanoyl)FLSPADMQKIAERQSQNKLRHGNM (SEQ ID NO: 16)GLT(n-decanoyl)FLSPADMQKIAERQSQNKLRHGNM (SEQ ID NO: 16)GLT(n-octanoyl)FLSPADMQKIAERQSQNKLRHGNMN (SEQ ID NO: 17) TilapiaGSS(n-octanoyl)FLSPSQKPQNKVKSSRI-NH₂ (SEQ ID NO: 18) CatfishGSS(n-octanoyl)FLSPTQKPQNRGDRKPPRV-NH₂ (SEQ ID NO: 19)GSS(n-octanoyl)FLSPTQKPQNRGDRKPPRVG (SEQ ID NO: 20) EquineGSS(n-butanoyl)FLSPEHHKVQHRKESKKPPAKLKPR (SEQ ID NO: 21) (wherein, anamino acid residue is written by the one letter notation defined byIUPAC and IUC)

These peptides are characterized by a specific structure due toacylation of hydroxyl group at the side chain of serine group (S) orthreonine group (T) by fatty acid such as octanoic acid or decanoicacid, and there has never been isolated the physiologically activepeptides having modifying hydrophobic group such as ghrelin. These newpeptides exhibit potent promoting effect for secretion of growthhormone, and it has become clear that these peptides perform foradjusting the secretion of growth hormone. Therefore, many researchershave great interest in physiologically active role of ghrelin and fordevelopment of these peptides as medicines (e.g., World PatentPublication WO 01/07475).

It is known that the modifying hydrophobic group in ghrelin molecule hasto be necessary for exhibiting the physiological effects (Kojima, etal., Nature, 402: 656-660, 1999). However, due to the non-existence ofpeptides like ghrelin having the modifying hydrophobic group in moleculeat the hydroxyl group of side chain of specific amino acid residue, thestability of these peptides for development as medicines have never beenstudied.

Incidentally, the compound to be developed as medicines has the variouskinds of chemical structures, and because of these chemical structures,the compounds may easily degrade in the formulation process or in thestorage process thereafter. The degradation reactions are hydrolyticcleavage, dehydration, isomerization, elimination, oxidization,reduction or photodegradation of the compound, and further, the chemicalreaction of the compound with additives to be formulated with thecompound. Therefore, it is very important to study and understand thevarieties of the degradation reaction and the degrees thereof from thechemical structure of the compounds, for development of the compound asmedicines, and consequence quality control thereof.

It is well known that the stability of medicines may be greatlycontrolled by the ambient environmental condition, such as pH level ofthe environment. The influence of pH of the solution for the degradationrate of medicines in aqueous state has been studied, and pH profile ofdegradation rate of many medicines has been reported (e.g., SumieYoshioka, “Stability of Medicines” by Nankohdo, 1995).

The physiologically active peptides or physiologically active proteinsare inactivated and degraded by protease existing in the digestiveorgan, and it is difficult to develop the oral administrable compositioncontaining these peptides or proteins. Therefore, these peptides orproteins are prepared as an injectable composition for the clinicaladministration, and for this purpose the stability of these substancesin the aqueous solution is very important for preparation of the liquidpharmaceutical formulations regardless of the dosage form such assolution form or soluble solution form in site.

At present, pharmaceutical compositions containing various kinds ofpeptide or protein such as insulin, growth hormone, calcitonin, atrialnatriuretic peptide, LH-RH (luteinizing hormone-releasing hormone)derivatives or adrenocorticotropic hormone derivatives are on sale asmedicines, and it is reported that the chemical changes of thesepeptides or proteins are deamidation, iso-aspartic acid formation,hydrolytic cleavage such as fragmentation, racemization, formation ofdisulfide bond or exchange reaction, β-elimination or oxidativereaction.

These chemical changes exert an influence on the stability of thecomposition containing peptides or proteins, and the degrees of thedegradation reaction of peptides or proteins is dependent on a pH valueof the solution. For example, it is reported that the chemical structureof degradation products and the produced amount of the degradationproducts varied according to the pH value of the solution containingthese peptides or proteins, such as LH-RH derivatives (Strickley et al.,Pharm. Res., 7, 530-536, 1990), human parathyroid hormone (Nobuchi etal., Pharm. Res., 14, 1685-1690, 1997), hirudin (antithrombin substance:Gietz et al., Pharm. Res., 15, 1456-1462, 1998), and human amylinderivatives (Hekmann et al., Pharm. Res., 15, 650-659 1998).

Ghrelin or its derivative of the present invention is a physiologicallyactive peptide, and it is common to prepare an aqueous solutioncontaining ghrelin as pharmaceutical composition for medicine. Thoughthe stability of ghrelin in the aqueous solution is very important forpreparation of the pharmaceutical composition, there has never been anystudy of the stability of ghrelin in the aqueous solution. Ghrelin orits derivative has the specific modifying hydrophobic group in itsmolecule, that is, the side chained hydroxyl group of certain amino acidresidue of ghrelin or its derivative is acylated by fatty acid. Therehas never been discovered a peptide like ghrelin having the specificmodifying hydrophobic group in molecule, therefore, the common knowledgeabout the stability of ghrelin has also never been reported. That is, itis unknown about the stability, the chemical structure of degradationproduct and the mechanism of production of the degradation product ofghrelin. Further, it is unknown about the mechanism of degradation ofmodifying hydrophobic group of ghrelin, as well as the secondarydegradation from the degradation product of ghrelin.

SUMMARY AND OBJECTS OF THE INVENTION

Under these circumstances, the objective of the present invention is toprovide a pharmaceutical composition stably containing ghrelin or itsderivative and a method for preventing degradation of modifyinghydrophobic group of ghrelin or its derivative in an aqueous solutiondissolved ghrelin or its derivative therein based on the knowledgeobtained by the investigation of the chemical stability of ghrelin orits derivative having specific modifying hydrophobic group in themolecule.

Through extensive investigations of the influence of pH in an aqueoussolution containing ghrelin and the chemical structure of thedegradation product from ghrelin, the present inventors discovered that,in an aqueous solution, ghrelin degraded to produce desacyl compound byhydrolytic cleavage of the specific modifying hydrophobic group and inaddition, degraded to produce dehydroalanine compound by β-eliminationof modifying hydrophobic group, consequently to produce the secondarydegradation product due to the volatility of dehydroalanine compound,and these degradation were affected by pH value of the aqueous solution.

Based on the results of the mechanism of degradation of ghrelinmentioned above, the present inventors further discovered that thepharmaceutical composition stably containing ghrelin could be obtainedby adjusting pH of the solution with pH adjuster or buffer agent, andthis stabilization effect could be obtained by various sorts of thebuffer agent independent of their concentration or grhelinconcentration, and thus completed the present invention.

Accordingly, as one aspect of the present invention, it is provided apharmaceutical aqueous composition containing ghrelin or its derivative(herein after and in claims refereed to as “the ghrelins”), wherein pHof an aqueous solution dissolving the ghrelins is from 2 to 7.

More specifically, the present invention provides the following:

-   (1) A pharmaceutical composition containing the ghrelins, wherein pH    of an aqueous solution dissolving the ghrelins is from 2 to 7.-   (2) A pharmaceutical composition according to (1), wherein said pH    is from 3 to 6.-   (3) A pharmaceutical composition according to (1) or (2), in which a    pH adjuster or a buffer agent is further contained.-   (4) A pharmaceutical composition according to (3), wherein the pH    adjuster is one or more selected from the group consisting of    hydrochloric acid, sulfuric acid, nitric acid, boric acid, carbonic    acid, bicarbonic acid, gluconic acid, sodium hydroxide, potassium    hydroxide, aqueous ammonia, citric acid, monoethanolamine, lactic    acid, acetic acid, succinic acid, fumaric acid, maleic acid,    phosphoric acid, methanesulfonic acid, malic acid, propionic acid,    trifluoroacetic acid and salt thereof.-   (5) A pharmaceutical composition according to (3), wherein the    buffer agent is one or more selected from the group consisting of    glycine, acetic acid, citric acid, boric acid, phthalic acid,    phosphoric acid, succinic acid, lactic acid, tartaric acid, carbonic    acid, hydrochloric acid, sodium hydroxide and the salt thereof.-   (6) A pharmaceutical composition according to any one of (3) to (5),    wherein concentration of the pH adjuster or the buffer agent in the    solution is in the range of from 0.01 mM to 100 mM.-   (7) A pharmaceutical composition according to any one of (1) to (6),    wherein the solution is buffer solution.-   (8) A pharmaceutical composition according to (7), wherein the    buffer solution is glycine hydrochloride buffer, acetate buffer,    citrate buffer, lactate buffer, phosphate buffer, citric    acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate    buffer.-   (9) A pharmaceutical composition according to any one of (1) to (8),    wherein the concentration of the ghrelins in the solution is in the    range of 0.03 nmol/mL to 6 μmol/mL.-   (10) A pharmaceutical composition according to any one of (1) to    (9), wherein the ghrelins is acetic acid salt.-   (11) A pharmaceutical composition according to any one of (1) to    (10), wherein the ghrelins is human ghrelin.-   (12) A pharmaceutical composition according to any one of (1) to    (11), wherein an anti-adsorbent is further contained.-   (13). A pharmaceutical composition according to (12), wherein the    concentration of the anti-adsorbent is in the range of from 0.001%    to 5%.-   (14) A pharmaceutical composition according to (12) or (13), wherein    the anti-adsorbent is surfactant.-   (15) A pharmaceutical composition containing the ghrelins, in which    powder obtained from a solution of any one of (1) to (14) by drying    is contained.-   (16) A pharmaceutical composition according to (15), wherein the    powder is a lyophilized powder.-   (17) A method for preventing a degradation of hydrophobic group of    the ghrelins in a solution containing the ghrelins which comprises    adjusting pH of the solution in the range of 2 to 7.-   (18) A method according to (17), wherein said pH of the solution is    adjusted to 3 to 6.-   (19) A method according to (17) or (18), wherein a pH adjuster or a    buffer agent is further contained.-   (20) A method according to (19), wherein one or more pH adjuster    selected from the group consisting of hydrochloric acid, sulfuric    acid, nitric acid, boric acid, carbonic acid, bicarbonic acid,    gluconic acid, sodium hydroxide, potassium hydroxide, aqueous    ammonia, citric acid, monoethanolamine, lactic acid, acetic acid,    succinic acid, fumaric acid, maleic acid, phosphoric acid,    methanesulfonic acid, malic acid, propionic acid, trifluoroacetic    acid and salt thereof is contained.-   (21) A method according to (19), wherein one or more buffer agent    selected from the group consisting of glycine, acetic acid, citric    acid, boric acid, phthalic acid, phosphoric acid, succinic acid,    lactic acid, tartaric acid, carbonic acid, hydrochloric acid, sodium    hydroxide and the salt thereof is contained.-   (22) A method according to any one of (19) to (21), wherein    concentration of the pH adjuster or the buffer agent in the solution    is in the range of 0.01 mM to 1000 mM.-   (23) A method according to any one of (17) to (22), wherein the    solution is buffer solution.-   (24) A method according to (23), wherein the buffer solution is    glycine hydrochloride buffer, acetate buffer, citrate buffer,    lactate buffer, phosphate buffer, citric acid-phosphate buffer,    phosphate-acetate-borate buffer or phthalate buffer.-   (25) A method according to any one of (17) to (24), wherein the    concentration of the ghrelins in the solution is in the range of    0.03 nmol/mL to 6 μmol/mL.-   (26) A method according to any one of (17) to (25), wherein the    ghrelins is acetic acid salt.-   (27) A method according to any one of (17) to (26), wherein the    ghrelins is human ghrelin.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the HPLC chart regarding the degradation patterns ofdesacyl compound and Dha compound in an aqueous solution of the ghrelinsin Example 1.

FIG. 2 is the graphic chart showing the profile of pH-degradationkinetic constant of the ghrelins.

FIG. 3 is the graphic chart showing the production amount of thedegradation product of the ghrelins in aqueous solution having variouskinds of pH.

FIG. 4 is the graphic chart showing pH stability of the ghrelins invarious kinds of buffer solution.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The pharmaceutical composition of the present invention will now beexplained more specifically as following.

The ghrelins to be used in the present invention are endogenous growthhormone secretagogues, which are peptides having effect of increasingthe intracellular calcium ion concentration and inducing the secretionof growth hormone. The suitable ghrelins are those obtained from human,rat, porcine, chicken, eel, bovine, equine, ovine, frog, trout orcanine. In the present invention, the ghrelins obtained from human ispreferably used, and more preferably, human ghrelin obtained from humanand having 28 amino acid residues is used.

The modifying hydrophobic group, which is a characteristic of theghrelins, is not limited to octanoyl (C₈) group, and is a residue offatty acid having 2 to 20, preferably 4 to 12 carbon atoms, such ashexanoyl (C₆) group, decanoyl (C₁₀) group or dodecanoyl (C₁₂) group.Further, the hydrophobic group is a residue of branched, saturated orunsaturated fatty acid, a residue of fatty acid having an aromatic groupsuch as phenylpropionyl group, and an adamantane skeleton.

Therefore, the ghrelin derivatives of the present invention include thepeptides listed in the above-mentioned Table 1, in which the amino acidsequence is modified by the insertion, addition and deletion of one ormore amino acid, and/or the substitution by other amino acid to saidamino acid sequence, and is modified chemically if necessary. Further,the ghrelin derivatives of the present invention include the peptides inwhich modifying hydrophobic group is bonded to amino acid chain by esterbond and having same physiologically activity as the ghrelins.

The ghrelins to be used in the pharmaceutical composition of the presentinvention include free form peptides and salts thereof. The free formpeptide and salt thereof can be reciprocally converted. The free formpeptide can be converted to a pharmaceutically acceptable salt byreacting with an inorganic or an organic acid. The examples of the saltinclude the salt with the inorganic acid, such as carbonate,bicarbonate, hydrochloride, sulfate, nitrate or borate; and the saltwith the organic acid, such as succinate, acetate, propionate ortrifluoroacetate. Further, the salt with alkali metal such as sodiumsalt or potassium salt; the salt with alkali earth metal such as calciumsalt or magnesium salt; the salt with organic amine such astriethylamine salt; and the salt with basic amino acid such alginic acidsalt is included. The peptides of the present invention can exist asmetal complex such as copper complex or zinc complex.

The form of the salt as mentioned above has an important role for thestability of the ghrelins. That is, pH values of the aqueous solution ofthe salts above are different from each other, and therefore, thesesalts play the role as pH adjuster for the aqueous solution of theghrelins.

The origins and the manufacturing methods of the ghrelins are notlimited in the present invention. The ghrelins obtained by chemicalprocess, semichemical process, genetical process or combination processthereof, and extraction from living body can be used in the presentinvention.

The ghrelins to be used as raw materials for medicines are commonlysupplied as lyophilized powder after purified by reverse liquidchromatography and so on.

The aqueous solution or solution of the present invention are thesolution used water as the solvent; however, other solvent such asethanol, 2-propanol and the like can be used within a pharmaceuticallyacceptable range.

The concentration of the ghrelins in the pharmaceutical composition ofthe present invention is not limited, and is preferably within apharmaceutically acceptable range. The lower limit of concentration isthe concentration wherein the ghrelins exhibit the pharmacologicallyactivities, and the upper limit of concentration is the concentrationwherein the ghrelins can be dissolve in the aqueous solutions. Theconcentration commonly used as medicines such as 0.03 nmol/mL to 6μmol/mL is preferable, and more preferably, the concentration of 0.03nmol/mL to 3 μmol/mL is used.

In the physiological composition of the present invention stablycontaining the ghrelins, the pH value of the solution is in the range of2 to 7, more preferably 3 to 6. It was found out that the stable pHvalue of the solution containing the ghrelins is in the range of 2 to 7.The adjustment of pH of the solution containing the ghrelins isconducted with pH adjuster or buffer agent.

Examples of pH adjuster include hydrochloric acid, sulfuric acid, nitricacid, boric acid, carbonic acid, bicarbonic acid, gluconic acid, sodiumhydroxide, potassium hydroxide, aqueous ammonia, citric acid,monoethanolamine, lactic acid, acetic acid, succinic acid, fumaric acid,maleic acid, phosphoric acid, methanesulfonic acid, malic acid,propionic acid, trifluoroacetic acid, and salt thereof.

Examples of buffer agent include glycine, acetic acid, citric acid,boric acid, phthalic acid, phosphoric acid, succinic acid, lactic acid,tartaric acid, carbonic acid, hydrochloric acid, sodium hydroxide, andthe salt thereof. Among them, glycine, acetic acid or succinic acid arepreferably used as buffer agent.

Considering the stability of the ghrelins in the aqueous solution, it isdesired that the fluctuation of pH values of the solution have to bereduced. Therefore, the pharmaceutical composition of the presentinvention is the solution having buffer capacity, that is, the buffersolution.

The buffer solution having the pH range wherein the degradation of theghrelins is inhibited is used, and the solution having the pH range of 2to 7, more preferably 3 to 6 is used. The suitable buffer solution isglycine hydrochloride buffer, acetate buffer, citrate buffer, lactatebuffer, phosphate buffer, citric acid-phosphate buffer (includingMcllvaine buffer), phosphate-acetate-borate buffer (includingBritton-Robinson buffer), and phthalate buffer. The examples of thecomponents of each buffers include the buffer agents mentioned above.

The concentration of pH adjuster is not limited and can be theconcentration commonly used to adjust the solution with the desired pHrange, and in general, the concentration of 0.01 to 100 mM is used.

Further, the concentration of buffer agent is also not limited and canbe the concentration maintaining the buffer capacity. Generally, theconcentration of 0.01 to 100 mM, preferably 0.1 to 100 mM, morepreferably 1 to 100 mM is commonly used.

According to the present invention, the pharmaceutical compositionstably containing the ghrelins in the aqueous solution is provided. Thecomposition contains other additives in consideration of osmolality,solubility, low irritation of the solution, as well as antisepsis effectand prevention of absorption of the ingredient in the solution.

In general, there is fear that in the pharmaceutical aqueous solutioncontaining peptides or proteins, the peptides or proteins adsorb tovessels used in the process for producing the solution or during theadministering of the solution, and therefore, the concentration ofpeptides or proteins decrease. In the case of the pharmaceuticalcomposition of the present invention, it was confirmed that the ghrelinsadsorb to glass vessels or polypropylene vessels in the range of theconcentration of the ghrelins for medical use. Therefore, it ispreferable to contain the anti-adsorbent to prevent the adsorption ofthe ghrelins to vessels. Examples of anti-adsorbent include surfactants,saccharides, amino acids and proteins.

The surfactant of the present invention include the surfactants listedin the “Handbook of PHARMACEUTICAL EXCIPIENTS” as well as the compoundshaving surface-active effects, and the suitable surfactant is selectfrom these surfactants. Examples include quaternary ammonium salts,polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters,parabens, polyethylene glycols, phospholipids, bile acids,polyoxyethylene castor oils, poyloxyethylenes, polyoxyethylenepolyoxypropylenes, polyalcohols, anionic surfactant, synthetic orsemi-synthetic polymers. Among them, polyoxyethylene sorbitan fatty acidesters and sorbitan fatty acid esters are preferably used.

The suitable quaternary ammonium salts include benzalkonium chloride,benzethonium chloride and cetylpyridinium chloride.

The suitable polyoxyethylene sorbitan fatty acid esters includepolyoxyethylene sorbitan monolaurate (Polysorbate® 20 or Tween® 20),polyoxyethylene sorbitan monopalmitate (Polysorbate® 40 or Tween® 40),polyoxyethylene sorbitan monostearate (Polysorbate® 60 or Tween® 60),polyoxyethylene sorbitan tristearate (Polysorbate® 65 or Tween® 65),polyoxyethylene sorbitan monooleate (Polysorbate® 80 or Tween® 80), andpolyoxyethylene sorbitan trioleate (Polysorbate® 85 or Tween® 85).

The suitable sorbitan fatty acid esters include sorbitan monolaurate(Span® 20), sorbitan monopalmitate (Span® 40), sorbitan monostearate(Span® 60), sorbitan monooleate (Span® 80), sorbitan trioleate (Span®85), and sorbitan sesquioleate.

The suitable parabens include methyl paraoxybenzoate, ethylparaoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, andisobutyl paraoxybenzoate.

The suitable polyethylene glycols include gylcofurol (gylcofurol 75),Mcrogol® 400 (polyethylene glycol 400), Mcrogol® 600 (polyethyleneglycol 600), and Mcrogol® 4000 (polyethylene glycol 4000); the suitablephospholipids include refined soybean lecithin and refined yolklecithin; and suitable bile acids include sodium desoxycholic acid.

The suitable polyoxyethylene castor oils include polyoxyethylene castoroil, polyoxyethylene hydrogenated castor oil, polyoxyethylenehydrogenated castor oil 50, and polyoxyethylene hydrogenated castor oil60. Examples of other poyloxyethylenes include polyoxyethylene oleylether, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, andpolyoxyethylene lauryl sulfate salt.

The suitable polyoxyethylene polyoxypropylenes include polyoxyethylenepolyoxypropylene glycol (Pluronic®) and polyoxyethylene polyoxypropylenecetyl ether.

The suitable polyalcohols include glycerin (glycerol), propylene glycol,and monoglyceryl stearate; and the suitable anionic surfactants includealkyl ether sulfate such as sodium cetyl sulfate, sodium lauryl sulfateand sodium oleyl sulfate; alkyl sulfosuccinate such as sodium laurylsulfosuccinate. The suitable synthetic or semi-synthetic polymersinclude polyvinyl alcohol, carboxyvinyl polymer, polyvinyl pyrrolidoneand sodium polyacrylate.

Examples of saccharides include monosaccharide such as mannitol,glucose, fructose, inositol, sorbitol, and xylitol; disaccharide such aslactose, sucrose, maltose, and trehalose; polysaccharide such as starch,dextran, pullulan, alginic acid, hyaluronic acid, pectinic acid, phyticacid, phytin, chitin, and chitosan. Examples of dextrin includeα-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, dextrin, hydroxypropylstarch, and hydroxyl starch. Examples of celluloses includemethylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxypropylcellulose, and hydroxypropyl methylcellulose, sodium carboxymethylcellulose.

The suitable amino acids include glycine and taurine; and polyamino acidsuch as polyglutamic acid, polyaspartic acid, polyglycine andpolyleucine. The Examples of proteins include albumin and gelatin.

Non-human serum albumin can be used as anti-adsorbent for thepharmaceutical composition of the present invention when the compositionis used as a reagent for examination or as veterinary medicines;however, it is preferable to use human serum albumin when thecomposition is used for a medicine for treating human being.

These anti-adsorbents can be used in combination. The concentration ofthe anti-adsorbent is in the range wherein the amount of theanti-adsorbent is pharmaceutically acceptable one and the adsorption ofthe ghrelins to the vessel is inhibited and the aggregation of thecomponents does not occur during the manufacturing process or thelong-term storage. For example, the concentration of the anti-adsorbentis in the range of 0.001 to 5%, preferably from 0.01 to 1%.

The pharmaceutical composition of the present invention can containfurther additives for any purpose, and examples of the additives isselected from the “Handbook of PHARMACEUTICAL EXCIPIENTS 2000” (JapanPharmaceutical Excipients Council: Yakuji Nippoh Sha). These includeisotonizing agent such as sodium chloride and mannitol; antiseptic agentsuch as sodium benzoate; antioxidant such as sodium bisulfite, sodiumpyrosulfite and ascorbic acid; soothing agent such as lidocainehydrochloride and mepivacaine hydrochloride.

The manufacture of the pharmaceutical composition of the presentinvention is conducted by mean of the common procedure applied in thepharmaceutical field. For example, first, freeze dried ghrelin isdissolved in the purified water, and then, buffer agent, anti-adsorbentand other additives are also dissolved in another purified water. Thenthe resulting water solutions are combined and sterilize by filtrationif necessary, and the obtained solution is filled in ampoules or vialsto obtain the pharmaceutical composition containing the ghrelins of thepresent invention.

As the dosage form for the injectable preparation, there is in situpreparation for the pharmaceutical composition. This dosage form issuitable for the compound, which is unstable in the solution forlong-term storage. Therefore, the composition to prepare the solutioncontaining the ghrelins in situ is one of the injectable preparations ofthe present invention. The composition to prepare the solutioncontaining the ghrelins in situ can contain raw material of the ghrelinsfor medicines and other additives with necessary amounts in a solidstate. Further, the composition is obtained by drying the solutioncontaining the ghrelins and other additives with necessary amounts. Thedry technique of the solution can be the freeze-drying method or thespray drying method, and the freeze-drying method is preferred. Thesesolid compositions can be used as the solution with water in situ.

The pharmaceutical composition of the present invention can beadministered to the mammal (human, monkey, dog, mouse and so on) asmedicine. The applicable diseases or obtainable efficacies of thecomposition are the diseases concerning the deficient or decreasinggrowth hormone (GH) such as dwarfism, activating osteoblast orosteoanagenesis in normal adult, build-up of muscle quantity and musclestrength, improvement of physical capabilities in GH deficiency ofadult, severe schizophrenia in childhood, use in combination withgonadotropin for induction of ovulation, prevention of protein metabolicdisorder by administration of prednisone, acceleration of T-celltraining in severe immune deficiency disease, senile loss weight, andprevention of adipes enlargement and atrophy cutis.

Further, examples of the applicable diseases or obtainable efficaciesindirectly concerning the deficient or decreasing growth hormone (GH)include cardiovascular disease such as cardiac failure based on theincreasing effect of heart rate of the pharmaceutical composition of thepresent invention. The effects of the pharmaceutical composition of thepresent invention are not limited to the human being, and are growthpromotion of animals, reducing of fat, and so on, and these effects aremore strong than those obtained by administering GH. The pharmaceuticalcomposition of the present invention my use as appetite enhancer fortreating anorexia or anorexia nervosa by intravenously orintracerebroventricular administering due to the improvement in one'sappetite. Further, the pharmaceutical composition of the presentinvention my use for treating the dynamic disorder of stomach such asnon-ulcerous apepsia, idiopathic mild gastric atony, dynamic apepsia andreflux esophagitis.

Furthermore, the pharmaceutical composition of the present inventionexerts the acceleration effect of cell growth in bone marrow, intestineduodenum and intestinum jejunum, and therefore, use as protectant forintestinal mucosa, mucosa injury preventive agent in small intestineduring intravenously furnishing of nutrition, and osteoporosis.

Further, the pharmaceutical composition of the present invention may fortreating the following diseases, or improving the following bodilyfunctions. The examples of these diseases include stimulation ofreleasing growth hormone in aged person, prevention of catabolic sideeffect of glucocorticoid, treating and preventing of osteoporosis,stimulation of immune system, promotion of curing the injury, promotionof repair the bone fracture, treating for growth delay, treating forrenal failure or malfunction due to growth delay, treating for thephysiologically missing condition including deficiency of growth hormonein children and related to chronic ailment, treating for growth delaywith adiposis or growth delay related to adiposis, treating for growthdelay related to Prader-Willi syndrome and Turner's syndrome, promotionof recovery from burn injury and cut-back admission to hospital, growthdelay uterine, skeletal dysplasia, treating for hypercorticoidism andCushing's syndrome, induction of systaltic growth hormone, substitutionof growth hormone in stress patient, cartilaginous dysplasia, Noonan'ssyndrome, schizophrenia, ademonia, Alzheimer's disease, curing ofdelayed damages and therapy of psychosocial deprivation, therapy ofinsufficiency of lung function and respiratory dependence syndrome,decay of catabolism reaction of proteins after major surgery, proteinloss and decrease of cachexia due to the chronic diseases such as canceror AIDS, therapy of hyperinsulinaemia including nesidioblastosis,adjuvant therapy for induction of ovulation, stimulation for developmentof thymus, preventing the age-related atrophy of thymus function,therapy for patients with impaired immune systems, strength of muscle,improvement of motility, skin thickening of elderly people, metabolichomeostasis, maintenance of renal homeostasis, stimulating osteoblast,osteoanagenesis and chondrogenesis.

Further, in animals the pharmaceutical composition of the presentinvention is effective for growth promotion of animals, increasing milkand animal hair production, activation of immunologic systems of petanimal, therapy for age-related diseases of pet animal, growth promotionof farm animals, and increasing mutton hair production.

The pharmaceutical composition of the present invention is administeredby various kinds of administering route with an aqueous solution. Forexample, the pharmaceutical composition of the present invention isadministered in the form of injectable solution such as intravenousinjection, subcutaneous injection, intramuscular injection orintravenous drip. Further, the pharmaceutical composition of the presentinvention is administered by parenteral route such as nasal route,transpulmonary route, transdermic route or transmucosal route.Furthermore, the pharmaceutical composition of the present invention isparenterally administered in the form of ophthalmic solution or capsulefilled with the solution.

EXAMPLE

The stability of the ghrelins of the present invention is illustrated inmore detail by way of the following Tests and Examples, but it is to benoted that the present invention is not limited by those tests andexamples in any way.

In the following description, the following symbols are used to have theparticular meanings and the following test methods and the instrumentsare used while it is not stated otherwise.

[Symbols]

-   -   Dha: dehydroalanine    -   TFA: trifluoroacetic acid    -   HBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium        hexafluorophosphte    -   HOBt: 1-hydroxybenzotriazole    -   TIPS: tri-isopropylsilane    -   DIPEA: diisopropylethylamine    -   Fmoc: fluorenylmethoxycarbonyl    -   Boc: t-butyloxycarbonyl    -   tBu: t-butyl    -   Trt: trityl    -   DMAP: 4-dimethylaminopyridine    -   EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide    -   Pmc: 2,2,5,7,8-pentamethylchroman-6-sulfonyl        [Instruments]

-   (A) Automatic peptide synthesizer    -   Applied Biosystems: Automatic 433A peptide synthesizer

-   (B) HPLC systems for analysis    -   Instrument: Shimadzu LC-10A system    -   Column: YMC-Pack PROTEIN-RP (4.6 mmΦ×150 mm) or        -   YMC-Pack ODS-AM (4.6 mmΦ×250 mm)    -   Column temperature: 40° C.    -   Eluent: acetnitrile in 0.1% TFA, with linear gradient of max 50%        concentration.    -   Flow rate: 1 mL/min    -   Detection: UV (210 nm)    -   Loaded volume: 10 to 500 μL

-   (C) HPLC systems for aliquot    -   Instrument: Waters 600 Multisolvent Delivery System    -   Column: YMC-Pack ODS-A (20 mmΦ×250 mm) or        -   YMC-Pack PROTEIN-RP (20 mmΦ×250 mm)    -   Eluent: acetonitrile in 0.1% TFA or 5% acetic acid, with linear        gradient.    -   Flow rate: 10 mL/min    -   Detection: UV (210 and 260 nm)    -   Loaded volume: 1 to 2 mL (more than 2 mL, loaded by pump)

-   (D) Storage chamber    -   Constant temperature and humidity chamber LH-30    -   (Nagano Kagaku) 5° C./40° C.    -   Prefab type constant temperature and humidity chamber LH-20    -   (Nagano Kagaku) 25° C.

-   (E) Mass spectrum    -   Instrument: Finnigan MAT TSQ700    -   Ion source: ESI.    -   Detective ion mode: positive    -   Spray voltage: 4.5 kV    -   Capillary temperature: 250° C.    -   Mobile phase: 0.2% acetic acid in H₂O/methanol (1/1)    -   Flow rate: 0.2 mL/min    -   Scan area: m/z 300 to 1500

-   (F) Analysis of amino acid sequence    -   Instrument: Applied Biosystem 477A Sequencer (Perkin-Elmyer)

-   (G) Analysis of amino acid composition    -   Instrument: Amino acid analyzer L-8500 (Hitachi)    -   Sample: Hydrolyzed with 6M-HCl containing 0.1% phenol in sealed        tube at 110° C. for 24 hours.

REFERENCE EXAMPLE Synthesis of Human Ghrelin

Using the Automatic peptide synthesizer,Boc-Gly-Ser(tBu)-Ser(Trt)-Phe-Leu-Ser(tBu)-Pro-Glu(OtBu)-His(Boc)-Gln(Trt)-Arg(Pmc)-Val-Gln(Trt)-Gln(Trt)-Arg(Pmc)-Lys(Boc)-Glu(OtBu)-Ser(tBu)-Lys(Boc)-Lys(Boc)-Pro-Pro-Ala-Lys(Boc)-Leu-Gln(Trt)-Pro-Arg(Pmc)-HMPresin was synthesized from Fmoc-Arg(Pmc)-HMP-resin (Applied BiosystemsJapan; 472 mg 0.25 mmol) by repeated deletion of Fmoc and insertion ofFmoc-amino acid (provide that, Boc-glycine was used in the case ofglycine N-terminal) by HBTU/HOBt. The obtained protected peptide-resin(1.7 g) was treated with 1% TFA/5% TIPS/methylene chloride solution (15mL) for 30 minutes. The peptide-resin was collected and washed withmethylene chloride. (30 mL) for several times, and with 1% DIPEA (30 mL)then with methylene chloride (30 mL). The obtained Trt deletedpeptide-resin was swelled in N-methylpyrrolidone (10 mL) and the mixturewas reacted with octanoic acid (144.2 mg, 1.0 mmol) and EDC-HCl (192 mg,1.0 mmol) in the presence of DNAP (31 mg, 0.25 mmol) for 16 hours. Theresulting resin was collected by filtration and washed withN-methylpyrrolidone and methylene chloride respectively, and dried invacuo to obtain protected peptide-resin wherein side chain of serine at3-position was substituted by octanoyl group. Then, deprotection reagentconsisting of 88% TFA/5% phenol/2% TIPS/5% H₂O (15 mL) was added to theobtained resin and the mixture was stirred for 2 hours at roomtemperature. The resin was removed off by filtration and the filtratewas concentrated. The obtained residue was treated with ether to givethe precipitate, and collected by filtration. The precipitate was driedto give 900 mg of crude peptide. 200 mg of the obtained crude peptidewas dissolved in 10 mL of water and the solution was added to YMC-PackODS-A column (20 mmΦ×250 mm) and eluted by 5% TFA with linear gradientof 0 to 60% of acetonitrile for 60 minutes (flow rate: 10 mL/min). Theobjective eluted parts were collected and lyophilized to give 60 mg oftarget peptide (human ghrelin acetic acid salt: acetic acid content:10.9%). ESI-MS: 3371 (calculated: 3370.9)

-   Leu standard amino acid composition: Ser; 3.43 (4), Glx; 5.93 (6),    Gly; 1.01 (1), Ala; 1.00 (1), Val; 0.98 (1), Leu; 2 (2), Phe; 1.00    (1), Lys; 4.02 (4), His; 1.00 (1), Arg; 2.98 (3), Pro; 3.93 (4)    (theoretical volume are in parentheses).-   Analysis of amino acid sequence: The obtained peptide is identified    with human ghrelin (octanoyl-Ser at 3 position not detected).

Rat ghrelin or other the ghrelins were obtained by using the sameprocedure mentioned above.

In the following Example, the ghrelins obtained by the Reference Examplewas used.

Example 1 Structural Analysis of the Degradation Products of theGhrelins

It is necessary to know the degradation reaction of the ghrelins in theaqueous solution to secure the stability of ghrelin in the aqueoussolution. Therefore, the degradation process of ghrelin was estimated bythe structural analysis of the degradation products of the ghrelins byusing human ghrelin, which is one of the ghrelins.

The aqueous solution containing about 0.15 μmol/mL (0.5 mg/mL) of humanghrelin was obtained by dissolving about 5.0 μmol (17 mg) of humanghrelin in Britton-Robinson buffer solution (pH 7.0: adjusted by 0.04Mof phosphate/acetic acid/boric acid solution) and 0.2M sodium hydroxideaqueous solution. The obtained solution was filled in brownish glassampoules and the ampoules were sealed with fire. The each ampoules werestored at 40±1° C. for 4 and 14 days. The degradation products in theaqueous solutions after storage were detected by HPLC method and theresults were shown in FIGS. 1 (a) and (b).

As shown in FIG. 1 (a), 2 major peaks (degradation product B anddegradation product C) at 24 to 28 minutes were observed in thesolutions after stored at 40° C. for 4 days. The two degradation productB and degradation product C were collected and the structural analysisof these degradation products from human ghrelin was conducted asfollow.

The Degradation Product B:

The mass of this product showed 3245 by ESI-MS analysis, and wasidentified with the mass of desacylated human ghrelin (hereinafter,referred to as “desacyl compound”) obtained from the hydrolytic cleavageof octanoyl group of human ghrelin. Further, from the results of aminoacid sequence and amino acid composition analysis of the degradationproduct B, the amino acid composition and the amino acid sequence wereidentified with the theoretical volume of those of desacyl compound. Inconclusion, it was confirmed that the degradation product B was desacylcompound.

The Degradation Product C:

The mass of this product showed 3227 by ESI-MS analysis, and wasidentified with the mass of [3-Dehydroalanine]human ghrelin(hereinafter, referred to as “Dha compound”) obtained from theβ-elimination of octanoyl group of human ghrelin. Further, from theresults of ESI-MS, amino acid sequence and amino acid compositionanalysis of the product obtained by the degradation product C byreacting with excess ethanethiol in an aqueous solution neutralized with0.05M sodium hydroxide aqueous solution, the product was identified with[3-Ethylcysteine]human ghrelin. That is, the mass of 3289 by ESI-MS wasidentified with the calculated addition value of Dha compound (3227) andethanethiol (62), and ethylcysteine was detected from amino acidsequence and amino acid composition analysis. The product,[3-Ethylcysteine]human ghrelin, was obtained from Dha compound bynucleophilic reaction of ethanethiol. In conclusion, it was confirmedthat the degradation product C was Dha compound.

From the above-mentioned results, it was confirmed that the degradationproducts in the neutralized aqueous solution of human ghrelin, which isone of the ghrelins, were desacyl compound obtained from the hydrolyticcleavage of octanoyl group of human ghrelind and Dha compound obtainedfrom the β-elimination of octanoyl group of human ghrelin.

As shown in FIG. 1 (b), the HPLC results of the solution stored for 14days, several peaks (degradation product D, E and so on) were observedin addition to peaks of degradation product B and C. Then, the desacylcompound (degradation product B) and the Dha compound (degradationproduct C) were stored in aqueous solution to examine the mechanism ofproduction of these degradation products.

The desacyl compound or the Dha compound was dissolved inBritton-Robinson buffer solution (pH 7.0) to prepared an aqueoussolution containing about 0.15 μmol/mL (0.5 mg/mL) of the desacylcompound or the Dha compound in same manner described above. Theobtained solution was filled in brownish glass ampoules and the ampouleswere sealed with fire. The ampoules filled with desacyl compound werestored at 40±1° C. for 14 days, and the ampoules filled with Dhacompound were storage at 40±1° C. for 3 days. The degradation productsin the aqueous solutions after stored were detected by HPLC method andthe results were shown in FIGS. 1 (c) and (d).

As shown in FIG. 1 (c), one major peak at the same retention time (26minutes) as that of degradation product D in FIG. 1 (b) was observed inthe solutions containing desacyl compound, after stored at 40° C. for 14days. The degradation product at this peak was collected and ESI-MS,amino acid sequence and amino acid composition analysis were conducted.From the results of these analyses, this product was identified withdesacyl human ghrelin (3-28).

ESI-MS: 3101 (calculated value: 3100.5).

Further, as shown in FIG. 1 (d), one broad peak at the same retentiontime (36 minutes) as that of degradation product E in FIG. 1 (b) wasobserved in the solutions containing Dha compound, after stored at 40°C. for 3 days. The degradation product at this peak was collected andESI-MS, amino acid sequence and amino acid composition analysis wereconducted. From the results of these analyses, this product wasestimated to be [N^(α)—CO—C(═CH₂)—OH]human ghrelin(4-28) (hereinafter,referred to as “2nd degradation product of Dha compound”).

ESI-MS: 3083 (calculated value: 3083.5),

-   Amino acid composition: Identified with the estimated amino acid    composition.-   Amino acid sequence: No reaction from first amino acid residue.

Furthermore, in FIG. 1 (d), several small peaks were observed at about30 to 35 minutes. These peaks were also observed in FIG. 1 (b), and itwas estimated that these degradation products were produced from humanghrelin via Dha compound.

From the above-mentioned results, the degradation process of the aqueoussolution containing human ghrelin was confirmed that the desacylcompound or the Dha compound was produced from human ghrelin at thebeginning, and then, the desacyl human ghrelin (3-28) was produced byfragmentation of the desacyl compound and 2nd degradation product of Dhacompound and further products were produced by fragmentation of thedesacyl compound, respectively.

Therefore, it was confirmed that to obtain the stability of the ghrelinsin an aqueous solution, it was necessary to prevent the various type ofcleavage reactions at the hydrophobic group, which was thecharacteristic structure of the ghrelins.

Example 2 Stability of the Ghrelins in Buffer Solutions Having VariousKinds of pH Value (Stability Test 1)

The influence of pH value of the solution containing the ghrelins wasconducted using human ghrelin, which is one of the ghrelins.

Human ghrelin was dissolved in the following aqueous solutions in theconcentration of about 0.15 μmol/mL (0.5 mg/mL).

0.1M HCl aqueous solution (pH: 1.1)

Mcllvain buffer solutions (pH: 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0)

The pH was adjusted with 0.1M citric aqueous acid and 0.2M dibasicsodium phosphate aqueous solution.

Each solution were stored at 25±2° C. for 8, 24, 48 and 72 hoursrespectively, and the obtained solutions were detected by HPLC analysisin comparison to the solutions before storage. The peak area ratio ofhuman ghrelin, desacyl compound and Dha compound to the total area werecalculated. No significant changes of pH in solution before storage andafter storage were observed. The results were shown in Table 2.

TABLE 2 Peak area ratio to total peak area (%) pH Desacyl Dha ob- Humancom- com- served ghrelin ^(a)) pound ^(b)) pound ^(b)) pH 1 Before 1.198.89 0.27 0.21  8 hr. after 1.2 94.40 4.88 0.15 24 hr. after 1.2 86.0013.31  0.09 48 hr. after 1.2 74.62 24.63  0.04 72 hr. after 1.2 65.0434.17 0.00 pH 2 Before 2.0 99.07 0.10 0.20  8 hr. after 2.0 98.82 0.340.20 24 hr. after 2.0 98.24 0.89 0.23 48 hr. after 2.0 97.35 1.76 0.2472 hr. after 2.0 96.46 2.59 0.25 pH 3 Before 3.0 99.07 0.10 0.20  8 hr.after 3.1 98.98 0.20 0.20 24 hr. after 3.1 98.77 0.38 0.23 48 hr. after3.1 98.40 0.67 0.24 72 hr. after 3.1 98.03 0.98 0.25 pH 4 Before 4.099.07 0.09 0.20  8 hr. after 4.0 99.07 0.12 0.20 24 hr. after 4.0 98.920.21 0.21 48 hr. after 4.0 98.69 0.37 0.22 72 hr. after 4.0 98.44 0.510.23 pH 5 Before 5.0 99.06 0.10 0.21  8 hr. after 5.0 99.04 0.14 0.21 24hr. after 5.0 98.91 0.24 0.21 48 hr. after 5.0 98.59 0.45 0.23 72 hr.after 5.0 98.37 0.61 0.24 pH 6 Before 6.0 99.07 0.10 0.20  8 hr. after6.0 98.87 0.28 0.21 24 hr. after 6.0 98.28 0.70 0.26 48 hr. after 6.097.64 1.33 0.31 72 hr. after 6.0 96.92 1.97 0.35 pH 7 Before 7.0 98.970.16 0.22  8 hr. after 7.0 98.15 0.92 0.25 24 hr. after 7.0 96.18 2.700.43 48 hr. after 7.0 93.44 5.22 0.61 72 hr. after 7.0 90.75 7.67 0.79pH 8 Before 8.0 98.61 0.47 0.24  8 hr. after 7.9 94.73 3.92 0.68 24 hr.after 7.9 87.32 10.57  1.39 48 hr. after 7.9 76.95 19.54  2.39 72 hr.after 7.9 68.30 27.26  3.12 ^(a)) The place where ratio of peak area ofhuman ghrelin is below 98% is underlined. ^(b)) The place where ratio ofpeak area of desacyl compound or Dha compound below 1% is underlined.

As shown in Table 2 above, more than 3% of the desacyl compound wasproduced in the aqueous solution of human ghrelin at pH 1.0 and 8.0 inthe shortest time, such as storage for 8 hours. Further, more than 1% ofthe desacyl compound was produced in the aqueous solution of humanghrelin at pH 7.0 stored for 24 hours and at pH 2.0 and 6.0 stored for48 hours, and ratio of human ghrelin was less than 98%. On the contrary,the production of the desacyl compound and the Dha compound wasinhibited in the solution having the pH range of 3.0 to 5.0.

It was understood that the aqueous solution having the pH range of 2 to7, preferably 3 to 6 was suitable for inhibiting the production of thedesacyl compound and the Dha compound. Therefore, it was confirmed thatto obtain the stability of the ghrelins in an aqueous solution, it wasnecessary to adjust the pH of the solution to the range of 2 to 7,preferably 3 to 6 to prevent the various type of cleavage reactions atthe hydrophobic group, which is the characteristic structure of theghrelins.

Example 3 Stability of the Ghrelins in Buffer Solutions Having VariousKinds of pH Value (Stability Test 2)

Using different buffer solution from the buffer solution of the Example2, the stability of the ghrelins was conducted in the buffer solutionhaving various kinds of pH value.

Human ghrelin, which is one of the ghrelins, was dissolved in theBritton-Robinson buffer solutions which is adjusted by combining 0.04Mphosphoric acid-acetic acid-boric acid aqueous solution and 0.2M sodiumhydrate aqueous solution in appropriate ratio, having pH of 2.1, 3.1,4.0, 5.0, 6.0, 7.0 and 7.9 to obtain an aqueous solution containinghuman ghrelin in the concentration of about 0.15 μmol/mL (0.5 mg/mL).The obtained solution was filled in brownish glass ampoules and theampoules were sealed with fire. For the calculation of kinetic constant,the certain degrees of degradation products have to be occurred in theaqueous solution of the ghrelins, and therefore, the ampoules werestored at 40±1° C., which was severe conditions for storage. Theconcentration (residual ratio) of human ghrelin was conducted by HPLCwith time. At the same time, the pH of the solution was measured and itwas confirmed that there was no significant changes of pH in solution.

The kinetic constants in each pH solution were calculated from thesequential change of the residual ratio, and the results were shown inFIG. 2.

Further, the peak area ratios of desacyl compound and Dha compound tothe total area in each solution having various kinds of pH, after storedat 40° C. for 1 day, were shown in FIG. 3.

As shown in FIG. 2, it was confirmed that the pH range of the solutionstably containing human ghrelin was from 3 to 6. The residual ratios ofghrelin in the solutions having the pH of 3.1, 4.0, 5.0 and 6.0 weremore than 87%, and these value were exceeded the target value (85%).

Further, as shown in FIG. 3, the production of desacyl compound wasinhibited in the solution having the pH range of 3 to 6, and theproduction of Dha compound was inhibited in the solution having the pHrange of 2 to 7.

From the results mentioned above, it was understood that in the case ofusing Britton-Robinson buffer solution, the aqueous solution having thepH range of 2 to 7, preferably 3 to 6 was suitable for inhibiting theproduction of the desacyl compound and the Dha compound. Therefore, itwas confirmed that to obtain the stability of the ghrelins in an aqueoussolution, it was necessary to adjust the pH of the solution to 2 to 7,preferably 3 to 6 to prevent the various type of cleavage reactions atthe hydrophobic group, which was the characteristic structure of theghrelins.

Example 4 The Influence of the Varieties of Buffer Solution forStability of the Ghrelins (Test 1)

The stability of the ghrelins by using citrate buffer solution wasexamined.

Human ghrelin, which is one of the ghrelins, was dissolved in thecitrate buffer solutions having pH of 3.6, 4.0, 4.5 and 5.0 to obtain anaqueous solution containing human ghrelin in the concentration of about0.15 μmol/mL (0.5 mg/mL). The obtained solutions were filled in brownishglass ampoules and the ampoules were sealed with fire, then, eachampoules were stored at 40±1° C. for 2 weeks. After storage for 2 weeks,the HPLC analysis of the solutions was conducted to calculate theresidual ratio from the concentration of human ghrelin. The change of pHvalue was also measured.

These results were summarized in the following Table 3.

TABLE 3 pH of buffer Just after After storage for solution preparation40° C./2 weeks 3.5 Residual ratio (%) 100 89 pH (observed) 3.6 3.5 4.0Residual ratio (%) 100 88 pH (observed) 4.0 4.0 4.5 Residual ratio (%)100 86 pH (observed) 4.5 4.4 5.0 Residual ratio (%) 100 85 pH (observed)5.0 4.9

As shown in Table 3, the residual ratios of human ghrelin were from 85to 89% when human ghrelin was dissolved in citrate buffer solutionshaving the pH range of 3.5 to 5.0, and these values exceeded the targetvalue (85%). Further, no significant changes of pH in solution beforestorage and after storage were observed. Therefore, it was confirmedthat the stability of the ghrelins in citrate buffer solution wasobtained in the pH range of 3.5 to 5.0.

Example 5 The Influence of the Varieties of Buffer Solution forStability of the Ghrelins (Test 2)

The stability of the ghrelins was examined by using glycinehydrochloride buffer solution or acetate buffer solution.

Human ghrelin, which is one of the ghrelins, was dissolved in the 0.05Mglycine hydrochloride buffer solutions having pH of 2.5, 3.1, 3.6, 4.2,4.6 and 4.8, or in the 0.05M acetate buffer solution having pH of 3.1,3.5, 4.0, 4.5 and 5.0, to obtain an aqueous solution containing humanghrelin in the concentration of about 0.15 μmol/mL (0.5 mg/mL). Theobtained solutions were filled in brownish glass ampoules and theampoules were sealed with fire, then, each ampoules were stored at 40±1°C. for 2 weeks. After storage for 2 weeks, the HPLC analysis of thesolutions was conducted to calculate the purity. The change of pH valuewas also examined to confirm no significant changes of pH of solutionoccurred.

The residual ratios of human ghrelin in the each buffer solution ofvarious kinds of pH after storage for 2 weeks were summarized in FIG. 4.

As shown in FIG. 4, the residual ratios of human ghrelin were from 87 to97% when human ghrelin was dissolved in glycine hydrochloride buffersolution or acetate buffer solution having the pH range of 2.5 to 5.0,and these values exceeded the target value (85%).

From the results of the Example 2 (stability in Mcllvaine buffersolution) the Example 3. (stability in Britton-Robinson buffersolution), the Example 4 (stability in citrate buffer solution), and theExample 5 (stability in glycine hydrochloride or acetate buffersolution), it was confirmed that the pH adjustment of the solution wasimportant to obtain the stability of the ghrelins in aqueous solution,and the variety of buffer solution had no effect on the stability of theghrelins in aqueous solution.

Example 6 Stability of the Ghrelins in Aqueous Solution with VariousKinds of Concentrations

The stability of the ghrelins in aqueous solution with various kinds ofconcentration was examined.

Human ghrelin, which is one of the ghrelins, was dissolved in the 0.05Mglycine hydrochloride buffer solutions (pH 3.5) to obtain an aqueoussolution containing human ghrelin with following five concentrations,which are applicable for medical usage.

0.03 nmol/mL (0.1 μg/mL); 0.3 nmol/mL (1.0 μg/mL);

3.0 nmol/mL (10.0 μg/mL); 0.3 μmol/mL (1.0 mg/mL);

3 μmol/mL (10 mg/mL).

Each solutions were stored at 25±2° C. for 24 hours, and after storage,the HPLC analyses of each solutions were conducted to calculate theresidual ratios from the concentration of human ghrelin. The changes ofpH value were also examined to confirm no significant changes of pH insolutions occurred.

The residual ratio of the solution before storage was referred to as100%, and the residual ratio of each solution after storage and thechanges of pH value of each solution were summarized in the followingTable 4.

TABLE 4 Concentration Just after After storage for of h. ghrelinpreparation 25° C./24 hours 0.03 nmol/mL Residual ratio (%) 100 62 pH3.4 3.5 0.3 nmol/mL Residual ratio (%) 100 98 pH 3.5 3.5 3.0 nmol/mLResidual ratio (%) 100 98 pH 3.5 3.6 0.3 μmol/mL Residual ratio (%) 100101 pH 3.4 3.3 3 μmol/mL Residual ratio (%) 100 101 pH 3.4 3.3

As shown in Table 4, the solutions with high concentration of humanghrelin (0.3 nmol/mL, 3.0 nmol/mL, 0.3 μmol/mL and 3 μmol/mL) kept thestability of human ghrelin in the aqueous solutions during the storageat 25° C. for 24 hours, and no decrease of the residual ratios and thechanges of pH value were observed.

On the contrary, in the case of the solution with low concentration ofhuman ghrelin (0.03 nmol/mL), the residual ratio of the solution afterstorage was 62%; however, no significant change of pH value was observedand there was no degradation product such as desacyl compound or Dha onthe HPLC chart analysis. Therefore, it was confirmed that the decreaseof the residual ratio of human ghrelin in the solution might be thedecrease of the content of human ghrelin due to its adsorption to thewall of the vessel. Accordingly, it was decided that the solutions withlow concentration of human ghrelin (0.03 nmol/mL) also kept thestability of human ghrelin in the aqueous solution during the storage at25° C. for 24 hours.

In conclusion, it was confirmed that the ghrelins were stably containedin the pH adjusted buffer solution in the concentration range of about0.03 nmol/mL to about 3 μmol/mL.

Example 7 Stability of the Ghrelins in Aqueous Solution Having VariousKinds of pH Value (Test 1)

The stability of the ghrelins in aqueous solution with various kinds ofpH value was conducted by using human ghrelin, which is one of theghrelins.

Human ghrelin was dissolved in the purified water with about 0.03μmol/mL (0.1 mg/mL). The pH of this solution was 4.7. This solution wasdivided into quarter, and one portion was kept alone and the pH valuesof the remaining three portions were adjusted to pH 1.8 (with 17 mM ofhydrochloric acid), pH 3.9 (with 0.20 mM of hydrochloric acid) and pH7.8 (with 0.24 mM of sodium hydroxide) respectively, by adding alongwith hydrochloric acid or sodium hydroxide aqueous solution.

These four solutions were stored at 25±2° C. for 1 and 3 day, and afterstorage, the HPLC analyses of each solutions were conducted to calculatethe peak area ratio of human ghrelin, desacyl compound and Dha compoundto the total peak area.

The results were summarized in the following Table 5.

TABLE 5 Peak area ratio to total peak area (%) Desacyl Dha Human ghrelin^(a)) compound ^(b)) compound ^(b)) pH 1.8 Before 99.16 0.12 0.20 1 dayafter 97.68 1.46 0.31 3 days after 95.01 4.08 0.34 pH 3.9 Before 99.210.07 0.20 1 day after 99.19 0.09 0.20 3 days after 99.14 0.14 0.19 pH4.7 Before 99.20 0.06 0.20 1 day after 99.12 0.15 0.21 3 days after98.94 0.28 0.21 pH 7.8 Before 98.85 0.33 0.24 1 day after 94.78 3.650.86 3 days after 87.84 9.84 1.65 ^(a)) The place where ratio of peakarea of human ghrelin is below 98% is underlined. ^(b)) The place whereratio of peak area of desacyl compound or Dha compound below 1% isunderlined.

As shown in Table 5, more than 1% of the desacyl compound was producedin the aqueous solution of pH 1.8 and 7.8, and the ratio of humanghrelin was less than 98%, at only one day after storage. Further, theproduction ratio of Dha compound was more than 1% in the aqueoussolution of pH 1.8 and 7.8 after 3 days' storage. On the contrary, theproductions of the desacyl compound and Dha compound were inhibited inthe aqueous solution of pH 3.9 and 4.7.

Accordingly, it was well understood that the aqueous solution having thepH range of 2 to 7 is suitable for inhibiting the production of thedesacyl compound and the Dha compound. Therefore, it was confirmed thatto obtain the stability of the ghrelins in an aqueous solution, it wasnecessary to adjust the pH of the solution to 2 to 7 to prevent thevarious type of cleavage reactions at the hydrophobic group, which wasthe characteristic structure of the ghrelins.

Example 8 Stability of the Ghrelins in Aqueous Solution Having VariousKinds of pH Value (Test 2)

The stability of the ghrelins in aqueous solution with various kinds ofpH value was conducted by using human ghrelin(1-7)amide, which is one ofthe ghrelins.

Human ghrelin(1-7)amide is common amino acid sequence of the ghrelinsobtained from mammal, bird or fishes (cf. Table 1), and exhibits samebiological activity as human ghrelin (International Patent PublicationWO 01/07475).

Human ghrelin(1-7)amide was dissolved in the purified water with about0.12 μmol/mL (0.1 mg/mL). The pH of this solution was 5.0. This solutionwas divided into quarter, and one portion was kept alone and the pHvalues of the remaining three portions were adjusted to pH 1.8 (with 17mM of hydrochloric acid), pH 4.1 (with 0.05 mM of hydrochloric acid) andpH 7.9 (with 0.20 mM of sodium hydroxide) respectively, by adding withhydrochloric acid or sodium hydroxide aqueous solution.

These four solutions were stored at 25±2° C. for 1 and 3 day, and afterstorage, the HPLC analyses of each solutions were conducted to calculatethe peak area ratio of human ghrelin(1-7)amide, desacyl humanghrelin(1-7)amide and [3-dehydroalanine]-human ghrelin(1-7)amide to thetotal peak area.

The results were summarized in the following Table 6.

TABLE 6 Peak area ratio to total peak area (%) Human [3-Dehydro- ghrelinDesacyl human alanine] (1-7) ghrelin(1-7) human ghrelin amide ^(a))amide ^(b)) (1-7)amide ^(b)) pH 1.8 Before 98.39 0.98 0.02 1 day after95.40 3.75 0.07 3 days after 90.11 8.89 0.10 pH 4.1 Before 98.76 0.720.00 1 day after 98.68 0.73 0.03 3 days after 98.60 0.77 0.01 pH 5.0Before 98.69 0.70 0.00 1 day after 98.57 0.73 0.02 3 days after 98.510.79 0.06 pH 7.9 Before 98.22 1.12 0.03 1 day after 95.89 3.21 0.23 3days after 92.54 6.21 0.54 ^(a)) The place where ratio of peak area ofhuman ghrelin (1-7) amide is below 98% is underlined. ^(b)) The placewhere ratio of peak area of human ghrelin (1-7) amide or[3-dehydroalanine]-human ghrelin (1-7) amide below 1% is underlined.

As shown in Table 6, the ratio of human ghrelin(1-7)amide was less than98% in the aqueous solution of pH 1.8 and 7.9, at only one day afterstorage. On the contrary, the production of the degradation products wasinhibited in the aqueous solution of pH 4.1 and 5.0.

Accordingly, it was well understood that the aqueous solution having thepH range of 2 to 7 was suitable for the aqueous solution containinghuman ghrelin(1-7)amide, which is one of the ghrelins. Therefore, it wasconfirmed that to obtain the stability of the ghrelins in an aqueoussolution, it was necessary to adjust the pH of the solution to 2 to 7 toprevent the various type of cleavage reactions at the hydrophobic group,which was the characteristic structure of the ghrelins.

Example 9 Adsorption Inhibiting Effect of Anti-Adsorbents in AqueousSolution Containing the Ghrelins with Low Concentration

In the Example 6, it was shown that the ghrelins adhere to the wall ofthe vessel in the solution having medical applicable concentration ofthe ghrelins. Accordingly, the adsorption inhibiting effect ofanti-adsorbents in aqueous solution containing the ghrelins wasexamined.

As the anti-adsorbent, the surfactant, that is, polyoxyethylene sorbitanmonooleate (hereinafter, referred to as Tween® 80), and benzalkoniumchloride were selected.

Human ghrelin was dissolved in 5% mannitol-0.05M glycine hydrochloridebuffer solution (pH 3.5) with about 0.3 nmol/mL (1.0 μg/mL)concentration, which was the medical applicable concentration of theghrelins. The anti-adsorbent was added to this solution with 0.01% or0.1% concentration.

The human ghrelin concentrations of each solution were measured by HPLCmethod right after preparation, and these solutions were replaced inglass test tubes. After that, each solution were further replaced in newglass test tubes, and same operation was repeated for 5 and 10 times,then, the human ghrelin concentrations of each treated solution weremeasured by HPLC method. As a control, the solution not containinganti-adsorbent was examined.

Same procedure was repeated by using test tube made by polypropyleneinstead of glass test tube.

The results were summarizes in Table 7.

TABLE 7 Glass tube ^(a)) Polypropylene tube ^(b)) Anti-adsorbent Initial5 10 5 10 Species Conc. Conc. times times times times None — 100 0 0 5119 Tween 80 0.01% 100 17 0 90 90  0.1% 100 20 5 93 91 benzalkonium 0.01%100 81 64 97 96 chloride  0.1% 100 99 99 99 101 ^(a)) Asahi Techno-glassCo., Ltd.: 10 mL ^(b)) CORNING Co., Ltd.: 15 mL

As clearly shown in Table 7, the human ghrelin concentrations of thesolutions were greatly reduced after the replacements of the solution inboth cases using glass tubes and polypropylene tubes. Particularly, inthe case of using glass tubes, the human ghrelin concentration of thesolution was reduced to the level not detected by the HPLC analysis.

On the contrary, high adsorption inhibiting effect against polypropylenetube was observed when Tween® 80 was added to the solution with 0.01% or0.1% concentration, as anti-adsorbent, and also high adsorptioninhibiting effect against both glass tube and polypropylene tube wasobserved when benzalkonium chloride was added to the solution with 0.01%or 0.1% concentration, as anti-adsorbent.

Accordingly, it was well understood that Tween® 80 and benzalkoniumchloride have a beneficial effect on inhibiting the ghrelins adsorptionto the wall of the vessel, of the solution containing the ghrelins withthe medical applicable concentration. Therefore, it was confirmed thatthe anti-adsorbent was effective to prevent the adsorption of theghrelins during the manufacturing process, long-term storage andadministering process.

Example 10 Adsorption Inhibiting Effect of Saccharides in AqueousSolution Containing the Ghrelins with Low Concentration

In the Example 9, it was shown that adsorption of the ghrelins to thewall of the vessel of the solution was inhibited by usinganti-adsorbent. In this Example, the adsorption inhibiting effect ofsaccharides was examined.

As an aqueous solution of saccharide, 5% mannitol aqueous solution wasused. Human ghrelin was dissolved in 5% mannitol aqueous solution withabout 3 nmol/mL (10 μg/mL) and about 30 nmol/mL (100 μg/mL)concentration, which were the medical applicable concentration of theghrelins. The

The human ghrelin concentrations of each solution just prepared afterwere measured by HPLC method, and these solutions were replaced inpolypropylene test tube. After that, each solution were further replacedin new polypropylene test tube, and same operation was repeated for 5times totally, then, the human ghrelin concentrations of each treatedsolution were measured by HPLC method. As control, the physiologicalsaline solutions containing human ghrelin with about 3 nmol/mL (10μg/mL) and about 30 nmol/mL (100 μg/mL) concentration were examined.

The results were summarizes in Table 8.

TABLE 8 Anti-adsorbent Initial Polypropylene tube ^(b)) Species Conc. ofhuman ghrelin Conc. 5 times Physiological 10 μg/mL 100 32 saline 100μg/mL 100 89 5% mannitol 10 μg/mL 100 98 aqueous 100 μg/mL 100 99solution ^(b)) CORNING Co., Ltd.: 15 mL

As clearly shown in Table 8, the human ghrelin concentrations ofphysiological saline solutions were greatly reduced after thereplacements of the solution by using polypropylene test tube.Particularly, the human ghrelin concentrations of the solution wasreduced to 32% in the case of physiological saline solution containinghuman ghrelin with 10 μg/mL concentration.

On the contrary, high adsorption inhibiting effect against polypropylenetube was observed in the case of 5% mannitol aqueous solution containinghuman ghrelin with both 10 μg/mL and 100 μg/mL concentration.

Accordingly, it was well understood that saccharides showed a beneficialeffect on inhibiting the ghrelins adsorption to the well of the vessel,in the solution containing the ghrelins with the medical applicableconcentration, and therefore, it was confirmed that the saccharides wereeffective to prevent the adsorption of the ghrelins during themanufacturing process, long-term storage and administering process.

Example 11 Manufacture of the In Situ Preparation for Solution and itsStability

As the in situ preparation for the pharmaceutical composition of thepresent invention, lyophilized powder was prepared and the solubility ofthe powder was estimated.

Human ghrelin was dissolved in 5% mannitol-0.05M glycine hydrochloridebuffer solution (pH 3.5) with about 0.3 nmol/mL (1.0 μg/mL)concentration, and the human ghrelin concentration of this solution justafter preparation was measured by HPLC method, and pH value of thissolution was also measured. As the results, the human ghrelinconcentration was 1.0 μg/mL, and pH was 3.5. Then, this solution waslyophilized at −25° C. for 24 hours in vacuo, and the obtained powderwas further dried at 20° C. for 24 hours in vacuo. The obtainedlyophilized powder was white solid having good figure.

Then, this lyophilized powder was dissolved in the purified water, whichamount was same as the decreased amount from the beginning of thelyophilization, and the solubility of the lyophilized powder and the pHof the obtained solution were examined.

As the result, the solubility of the lyophilized powder was excellentand no insoluble matter appeared in the solution, and the solubility ofthe powder was suitable for the in situ preparation for solution. Thehuman ghrelin concentration was 1.0 μg/mL, which is same human ghrelinconcentration of the solution just after the preparation or before thelyophilization, therefore, no decrease of content of the preparation bylyophilization was observed. Further, the pH value of the solution was3.5, which was same pH value of the solution just after the preparationor before the lyophilization. Therefore, the aqueous solution stablycontaining human ghrelin can be obtained from the lyophilized powder ofthe present invention.

Accordingly, the lyophilized powder containing the ghrelins can beobtained by using the solution containing the ghrelins with adjustmentof pH of the solution by lyophilization, and obtained lyophilized powderpreparation is useful for the in situ preparation for the pharmaceuticalcomposition of the present invention.

Manufacturing Example 1 Preparation of Pharmaceutical CompositionContaining Human Ghrelin with pH Adjustment

Human ghrelin, which is one of the ghrelins, was dissolved in purifiedwater to obtain an aqueous solution containing human ghrelin with about0.15 μmol/mL (0.5 mg/mL). The pH of this solution was adjusted to 4.0 byadding 0.1M hydrochloride acid solution, to obtain the pharmaceuticalcomposition containing human ghrelin as the solution preparation.

Manufacturing Example 2 Preparation of Pharmaceutical CompositionContaining Rat Ghrelin in Glycine Hydrochloride Buffer Solution

Rat ghrelin, which is one of the ghrelins, was dissolved in 0.05Mglycine hydrochloride buffer solution (pH 3.5) with about 0.15 μmol/mL(0.5 mg/mL) to obtain the pharmaceutical composition containing ratghrelin as the solution preparation. The pH of this solution was 3.5.

Manufacturing Example 3 Preparation of Pharmaceutical CompositionContaining [3-Serine(Acetyl)]Human Ghrelin in Glycine HydrochlorideBuffer Solution

[3-Serine (acetyl)]human ghrelin, which is one of the ghrelins, wasdissolved in 0.05M glycine hydrochloride buffer solution (pH 3.5) withabout 0.15 μmol/mL (0.1 mg/mL) to obtain the pharmaceutical compositioncontaining [3-Serine(acetyl)]human ghrelin as the solution preparation.The pH of this solution was 3.5.

Manufacturing Example 4 Preparation of Pharmaceutical CompositionContaining [3-Serine(Phenylpropionyl)]Human Ghrelin in GlycineHydrochloride Buffer Solution

[3-Serine(phenylpropionyl)]human ghrelin, which is one of ghrelins, wasdissolved in 0.05M glycine hydrochloride buffer solution (pH 3.5) withabout 0.15 μmol/mL (0.5 mg/mL) to obtain the pharmaceutical compositioncontaining [3-Serine(phenylpropionyl)]human ghrelin as the solutionpreparation. The pH of this solution was 3.5.

Manufacturing Example 3 Preparation of Pharmaceutical CompositionContaining Human Ghrelin(1-5)Amide in Glycine Hydrochloride BufferSolution

Human ghrelin(1-5)amide, which is one of ghrelins, was dissolved in0.05M glycine hydrochloride buffer solution (pH 3.5) with about 0.15μmol/mL (0.5 mg/mL) to obtain the pharmaceutical composition containinghuman ghrelin(1-5)amide as the solution preparation. The pH of thissolution was 3.5.

INDUSTRIAL APPLICABILITY

As described above, the present invention provides the pharmaceuticalcomposition stably containing the ghrelins, and the preparation of thepresent invention prevents the adsorption of ghrelins to the wall of thevessel. Therefore, the present invention provides the pharmaceuticalcomposition without decrease of the ghrelins, during the manufacture,long-term storage or administration.

The invention claimed is:
 1. A pharmaceutical composition comprisingstable, physiologically-active ghrelin or its derivative in an aqueoussolution which dissolves said ghrelin, and further comprising a pHadjuster, wherein: said aqueous solution has an acidic pH ranging from 3to 6 to prevent the degradation of a hydrophobic group on the side chainof the serine or theronine at the third residue of said ghrelin, the pHadjuster comprises hydrochloric acid, sulfuric acid, nitric acid, boricacid, carbonic acid, bicarbonic acid, gluconic acid, sodium hydroxide,potassium hydroxide, aqueous ammonia, citric acid, monoethanolamine,lactic acid, acetic acid, succinic acid, fumaric acid, maleic acid,phosphoric acid, methanesulfonic acid, malic acid, propionic acid,trifluoroacetic acid, a salt thereof, or mixtures of said pH adjusters,and said composition is suitable for pharmaceutical administration to ahuman.
 2. The pharmaceutical composition of claim 1, further comprisinga buffer agent.
 3. The pharmaceutical composition of claim 2, whereinthe buffer agent comprises glycine, acetic acid, citric acid, boricacid, phthalic acid, phosphoric acid, succinic acid, lactic acid,tartaric acid, carbonic acid, hydrochloric acid, sodium hydroxide, thesalt thereof, or mixtures of said buffer agents.
 4. The pharmaceuticalcomposition of claim 2, wherein the concentration of the buffer agent inthe solution ranges from 0.01 mM to 1000 mM.
 5. The pharmaceuticalcomposition of claim 1, wherein the solution comprises a buffersolution.
 6. The pharmaceutical composition of claim 5, wherein thebuffer solution comprises glycine hydrochloride buffer, acetate buffer,citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphatebuffer, phosphate-acetate-borate buffer, phthalate buffer, or a mixtureof said buffer solutions.
 7. The pharmaceutical composition of claim 1,wherein the concentration of ghrelin in the solution ranges from 0.03nmol/mL to 6 μmol/mL.
 8. The pharmaceutical composition of claim 1,wherein the ghrelin is in the form of an acetic acid salt.
 9. Thepharmaceutical composition of claim 1, wherein the ghrelin compriseshuman ghrelin.
 10. The pharmaceutical composition of claim 1, furthercomprising an anti-adsorbent.
 11. The pharmaceutical composition ofclaim 10, wherein the concentration of the anti-adsorbent ranges from0.001% to 5%.
 12. The pharmaceutical composition of claim 10, whereinthe anti-adsorbent comprises a surfactant.
 13. The pharmaceuticalcomposition comprising the ghrelin of claim 1 in the form of a driedpowder obtained from a solution.
 14. The pharmaceutical composition ofclaim 13, wherein the powder comprises a lyophilized powder.
 15. Thepharmaceutical composition of claim 1, wherein saidphysiologically-active ghrelin or its derivative is present in an amounteffective to adjust the secretion of a growth hormone.